rhNRG-1 Obtained SFDA Approval for Phase III Clinical Trial
2010-03-05
rhNRG-1 was approved by SFDA to take phase III clinical trial (2010L00444). Based on the progress of previous clinical trials of rhNRG-1, Zensun expected to finish clinical study, new drug application (NDA) and manufacturing approval in two years. Zensun hope that rhNRG-1 could make breakthrough in heart failure drug development and provide benefit of the many millions of heart failure sufferers world-wide.
更多动态
Zensun is Collaborating with The Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. to Conduct a Preclinical Study of Neucardin® (recombinant human Neuregulin-1) for The Treatment of Schwannomas
ZENSUN ANNOUNCES THE INVESTIGATION OF NEUCARDIN FOR CHRONIC HEART FAILURE RECEIVES FAST TRACK DESIGNATION FROM THE US FDA
An International Multi-center Phase III Clinical Trial of Recombinant Human Neuregulin-1 is going to
